Filing summary
Issuer identity: The supplied 10-Q is for Trovagene, Inc. (Nasdaq: TROV), not Cardiff Oncology, Inc. It covers the quarter and six months ended June 30, 2019; financial statements are unaudited.
Business context and reporting period
Trovagene described itself as a clinical-stage oncology therapeutics company developing onvansertib, an oral PLK1 inhibitor, with biomarker-guided treatment programs. Its three active trials were in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer (mCRPC), and KRAS-mutated metastatic colorectal cancer (mCRC).
Financial performance and position
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $138,285 | $111,813 | $300,243 | $211,949 |
| Operating loss | $4.220 million | $4.440 million | $8.182 million | $9.095 million |
| Net loss | $4.125 million | $3.747 million | $8.030 million | $8.533 million |
| Net loss attributable to common stockholders | $4.131 million | $6.523 million | $8.310 million | $11.315 million |
| Basic and diluted loss per share | $(0.79) | $(5.27) | $(1.78) | $(11.27) |
- At June 30, cash and cash equivalents were $10.791 million; working capital was $8.126 million. Total assets were $13.868 million and total liabilities were $5.020 million.
- Operating cash used in the first half was $6.803 million, compared with $6.107 million in the prior-year period. Investing cash used was $5,274; financing cash provided was $6.147 million. Cash declined $662,000 from year-end 2018.
- The filing reports no outstanding equipment-line borrowing; that line had been paid off. Operating lease liabilities totaled $2.123 million. The filing does not report a separate conventional debt balance.
- Cost of revenue was zero in the 2019 quarter and first half, following disposition of the CLIA laboratory. A gross margin percentage is not presented and is not meaningful to infer from these reported figures.
Material changes versus the prior comparable period
- Q2 revenue increased $26,472 year over year; first-half revenue increased $88,294. Management attributed the increase mainly to sublease income recognized under the new lease accounting standard, partly offset by lower diagnostic service revenue after the laboratory disposition. Royalties declined slightly in the first half.
- Research and development expense rose 45% in Q2 to $2.830 million and 43% in the first half to $5.479 million, primarily from increased clinical-trial and outside-service costs for onvansertib.
- Selling, general and administrative expense fell to $1.528 million in Q2 and $3.003 million for the first half. Management cited reduced headcount, lower stock compensation, and a one-time executive severance expense and stock-option grants in 2018.
- The lower loss attributable to common stockholders largely reflected the absence of the $2.770 million Series B beneficial-conversion deemed dividend recorded in 2018; it should not be read as an equivalent reduction in cash burn. Weighted-average shares increased substantially year over year.
- The company adopted lease accounting standard ASC 842 in Q1 2019, recognizing right-of-use assets and lease liabilities. It also completed a 1-for-6 reverse stock split in February 2019; comparative per-share and share data were retroactively adjusted.
Outlook, commentary, and risks
- Management projected existing resources would fund planned operations into the first quarter of 2020, while stating that substantial doubt existed about the company’s ability to continue as a going concern. It expected significant ongoing losses and said additional capital would be needed.
- Management was evaluating equity financing, new revenue initiatives, cost reductions, and strategic partnerships. Funding might not be available on acceptable terms or at all; equity issuance could dilute shareholders. A funding shortfall could force trial delays, reductions, discontinuation, or unfavorable licensing or asset dispositions.
- For 2019, management planned further AML dose escalation and a Phase 2 segment after establishing the recommended Phase 2 dose; preliminary safety and efficacy updates; continued mCRPC evaluation; and enrollment and data updates for the mCRC trial. These are targets, not assurances.
- The company reported preliminary clinical observations, including responses in small patient groups, and preclinical combination findings. These early results do not establish efficacy or safety; trial outcomes and development timelines remain uncertain.
- Notable financing and dilution: in January, PoC Capital committed $1.675 million for clinical-study services in exchange for equity securities; in April and May, the company raised approximately $3.0 million gross through stock and warrant offerings, and it received approximately $3.3 million from warrant exercises. Common shares outstanding were 5,441,390 at June 30 and 5,445,764 at July 31.
- A related-party agreement with Leucadia Life Sciences, in which the CEO was a principal stockholder, was amended to $1.070 million; about $503,000 of related research and development expense was recorded in the first half.
- The filing reported no legal proceedings, no material changes to the prior annual report’s risk factors, and effective disclosure controls as of June 30. It reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm issuer identity: this filing is Trovagene, Inc., not Cardiff Oncology, Inc.
- Check subsequent filings and financing activity for cash runway, dilution, and whether the stated Q1 2020 funding horizon was extended.
- Review clinical-trial updates, enrollment, recommended dose determination, and whether preliminary responses were confirmed in larger datasets.
- Assess the cash operating burn alongside the non-cash deemed dividend and warrant fair-value gains when interpreting reported losses.
- Review the terms and accounting for the PoC clinical-trial funding commitment, Lincoln Park offerings, warrants, related-party arrangements, and lease obligations.